Hsbc Holdings PLC Has $208,000 Stock Position in BeOne Medicines Ltd. – Sponsored ADR $ONC

Hsbc Holdings PLC reduced its holdings in BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 80.9% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 707 shares of the company’s stock after selling 2,987 shares during the quarter. Hsbc Holdings PLC’s holdings in BeOne Medicines were worth $208,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in ONC. BNP Paribas Financial Markets lifted its position in shares of BeOne Medicines by 100.6% during the 4th quarter. BNP Paribas Financial Markets now owns 193,951 shares of the company’s stock valued at $58,924,000 after acquiring an additional 97,244 shares during the period. Capital International Sarl grew its holdings in BeOne Medicines by 2.7% in the fourth quarter. Capital International Sarl now owns 152,515 shares of the company’s stock worth $46,336,000 after purchasing an additional 3,956 shares during the period. Slow Capital Inc. grew its holdings in BeOne Medicines by 51.5% in the fourth quarter. Slow Capital Inc. now owns 27,301 shares of the company’s stock worth $8,294,000 after purchasing an additional 9,280 shares during the period. Capital International Investors increased its stake in BeOne Medicines by 1.3% in the fourth quarter. Capital International Investors now owns 5,113,866 shares of the company’s stock valued at $1,553,909,000 after purchasing an additional 67,808 shares in the last quarter. Finally, UBS Group AG raised its holdings in shares of BeOne Medicines by 45.0% during the fourth quarter. UBS Group AG now owns 152,087 shares of the company’s stock valued at $46,206,000 after purchasing an additional 47,172 shares during the period. 48.55% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently commented on the company. Wells Fargo & Company initiated coverage on BeOne Medicines in a research note on Monday, May 4th. They issued an “overweight” rating and a $400.00 target price for the company. JPMorgan Chase & Co. upped their price target on BeOne Medicines from $415.00 to $425.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Leerink Partners increased their price target on BeOne Medicines from $364.00 to $367.00 and gave the stock an “outperform” rating in a report on Friday, May 15th. Truist Financial raised their price objective on BeOne Medicines from $413.00 to $416.00 and gave the company a “buy” rating in a research note on Tuesday, July 7th. Finally, Wall Street Zen upgraded BeOne Medicines from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 18th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, BeOne Medicines currently has a consensus rating of “Moderate Buy” and a consensus price target of $394.00.

BeOne Medicines Trading Down 0.7%

NASDAQ:ONC opened at $313.77 on Tuesday. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27. BeOne Medicines Ltd. – Sponsored ADR has a one year low of $253.95 and a one year high of $385.22. The company has a market cap of $34.43 billion, a PE ratio of 70.19 and a beta of 0.49. The firm has a 50-day moving average of $293.57 and a 200-day moving average of $308.92.

BeOne Medicines (NASDAQ:ONC) last announced its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. The business had revenue of $1.51 billion for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. As a group, equities research analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 5.93 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO John Oyler sold 145,861 shares of BeOne Medicines stock in a transaction that occurred on Tuesday, July 14th. The stock was sold at an average price of $305.95, for a total transaction of $44,626,172.95. Following the transaction, the chief executive officer owned 8,122 shares of the company’s stock, valued at $2,484,925.90. The trade was a 94.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Xiaobin Wu sold 1,484 shares of BeOne Medicines stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $269.37, for a total value of $399,745.08. Following the transaction, the chief operating officer directly owned 40 shares in the company, valued at approximately $10,774.80. The trade was a 97.38% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 344,404 shares of company stock worth $105,264,141 in the last 90 days. Corporate insiders own 6.19% of the company’s stock.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.